PRESS OFFICE
LISTING
Homenewsabout usContact UsWebsite
Welcome to the
Cipla Press Office
Cipla is a global pharmaceutical company whose goal is ensuring no patient shall be denied access to high quality & affordable medicine and support.
Follow us:
 
News

Latest news

Alvotech and Cipla partner to ensure access to biosimilars in South AfricaBiopharmaceutical company Alvotech and Cipla Medpro, a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as "Cipla"), have entered into an exclusive partnership to bring key biosimilars to patients in emerging markets such as South Africa. The biosimilar portfolio will include five biosimilar medicines - two for oncology and three for treating auto-immune diseases. 5 Nov 2020 Read more

IDA awards top industry honour to Greater Tygerberg PartnershipIDA presents awards recognising innovative achievement in urban place management 12 Oct 2020 Read more

Covid-19 drug, Remdesivir, arrives in SARemdesivir, a medicine which could make a difference in the management of severe Covid-19 disease, is available in South Africa now. Cipla obtained authorisation from the South African Health Products Regulatory Authority ("SAHPRA") to import this medicine under Section 21 of the Medicines and Related Substances Act. Cipla is working closely with SAHPRA and healthcare facilities to ensure access to remdesivir. 4 Aug 2020 Read more

Cipla gets ready to bring Covid-19 treatment to SACipla through a landmark agreement with Gilead Sciences Inc., was granted a license to manufacture and distribute the antiviral medicine, remdesivir, in 127 countries, including South Africa. As many of these countries are low-income countries and emerging markets that face obstacles in accessing healthcare, Cipla will expand supply to several sub-Saharan African countries. 6 Jul 2020 Read more


More news...

Contact Cipla

Email: az.oc.alpic@ofni
Tel: +27 21 943 4200
Customer Care: 080 222 6662
Website: www.cipla.co.za